Evolocumab · Repatha
Monoclonal antibody
Also known as AMG 145
Evidence outlook
Approved: Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (5)
- New indication: adults with established atherosclerotic cardiovascular disease, to reduce the risk of myocardial infarction, stroke and coronary revascularization
- Homozygous familial hypercholesterolemia in adults and adolescents over 12 years
- Familial hypercholesterolemia and hypercholesterolemia at high cardiovascular risk not adequately controlled by statins
- Prevention of Cardiovascular Events Repatha® (evolocumab injection) is indicated as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid- lowering therapy), to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adult patients with atherosclerotic cardiovascular disease (ASCVD) by further lowering low-density lipoprotein cholesterol (LDL-C) levels (see 14 CLINICAL TRIALS). Primary Hyperlipidemia (including Heterozygous Familial Hypercholesterolemia [HeFH] and ASCVD)...
- Primary hypercholesterolaemia, mixed dyslipidaemia, homozygous familial hypercholesterolaemia; label now includes established atherosclerotic cardiovascular disease
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
DESCARTES NCT01516879 · Hypercholesterolemia The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome. Registry: NCT01516879 | 3 | Percent Change From Baseline in LDL-C at Week 52 (Baseline and Week 52) 2013-10-14 | Percent Change From Baseline in LDL-C at Week 52 (Baseline and Week 52): Evolocumab -50.14% (Standard Error 1.24) vs Placebo 6.83% (Standard Error 1.75) | Partial signal | link ↗ |
View 10 more trials
TESLA NCT01588496 · Homozygous Familial Hypercholesterolemia The randomized, quadruple-blind, placebo-controlled Part B (n=49) used a hard, regulator-accepted endpoint (LDL-C change from baseline) and the primary comparison was statistically significant and strongly favored evolocumab (LS mean difference -30.93%, 95% CI -43.86 to -18.00, p<0.001). Part A was an open-label single-arm pilot, but the grade is based on the randomized placebo-controlled Part B, which provides strong evidence for the drug. Registry: NCT01588496 | 2/3 | Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12); Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12) 2014-01-31 | Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 | Reliable signal | link ↗ |
FOURIER NCT01764633 · Atherosclerotic Cardiovascular Disease Participants were randomized to evolocumab or placebo and the trial was quadruple-blind, with 13,784 participants receiving evolocumab and 13,780 receiving placebo. The hard clinical primary endpoint was met in favor of evolocumab (hazard ratio 0.85, 95% CI 0.79–0.92; p<0.0001), but the available record does not report a power calculation confirming that the enrollment met the prespecified sample-size requirement. Registry: NCT01764633 | 3 | Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization (Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.) 2016-11-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
EBBINGHAUS NCT02207634 · Atherosclerotic Cardiovascular Disease Participants were assigned to evolocumab or placebo and remained blinded, with 1,974 enrolled; the primary computerized cognitive-function endpoint met its prespecified non-inferiority criterion, with a treatment difference of 0.0072 (95% CI −0.0664 to 0.0808) versus a margin of 0.19. The study is graded moderate because the available record does not report the power calculation required to confirm that enrollment was adequate. Registry: NCT02207634 | 3 | Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).) 2016-11-11 | Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877) | Partial signal | link ↗ |
LAPLACE-2 NCT01763866 · Atherosclerotic Cardiovascular Disease This was a large, quadruple-blind, placebo- and ezetimibe-controlled randomized trial in which evolocumab produced a substantially greater reduction in LDL-C at Week 12 than either comparator, with every primary comparison statistically significant (p<0.001). The design is otherwise exemplary, but the record does not report a power (sample-size) calculation for the primary endpoint, so it cannot be confirmed that the trial was adequately powered for that comparison, which keeps the evidence short of the top tier. Registry: NCT01763866 | 3 | Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12); Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 (Baseline and Weeks 10 and 12) 2013-11-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
MENDEL-2 NCT01763827 · Atherosclerotic Cardiovascular Disease The trial randomized 615 participants to evolocumab, placebo, or ezetimibe and used quadruple blinding. Both prespecified LDL-C primary endpoints were significantly met, but no primary-endpoint power calculation is reported in the provided record, so the evidence is graded moderate despite the strong randomized, blinded design. Registry: NCT01763827 | 3 | Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12); Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 (Baseline and Weeks 10 and 12) 2013-10-10 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
RUTHERFORD-2 NCT01763918 · Atherosclerotic Cardiovascular Disease The trial was randomized, quadruple-blind, and placebo-controlled, enrolling 331 participants, and its primary LDL-cholesterol endpoint is an objective, regulator-accepted measure for lipid-lowering treatment. Both primary comparisons significantly favored evolocumab (p<0.001), but no primary-endpoint power calculation is reported in the provided record, so the evidence is graded moderate rather than strong. Registry: NCT01763918 | 3 | Percent Change From Baseline in LDL-C at Week 12 (Baseline and Week 12); Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 (Baseline and Weeks 10 and 12) 2013-11-27 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
HAUSER-RCT NCT02392559 · Atherosclerotic Cardiovascular Disease This was a randomized, triple-blind, placebo-controlled trial, and evolocumab clearly met its LDL cholesterol primary endpoint (difference -38.3%, p<0.0001). The posted protocol reports a sample-size calculation requiring 150 randomized children, and 158 were randomized. Registry: NCT02392559 | 3 | Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24) 2019-11-25 | Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) | Reliable signal | link ↗ |
TAUSSIG NCT01624142 · Atherosclerotic Cardiovascular Disease This was a single-group, open-label study in which all 300 participants with severe familial hypercholesterolemia received evolocumab, with no randomization, blinding or comparator arm. Most participants (246 of 300) enrolled directly, and only 54 rolled over from an earlier evolocumab study. The primary endpoint was the number of participants with adverse events: 94 of 106 participants with homozygous disease and 174 of 194 with severe non-homozygous disease reported at least one adverse event. Lipid changes were secondary, uncontrolled measures. Registry: NCT01624142 | 2/3 | Number of Participants With Adverse Events (From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months.) 2018-05-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
HAUSER-OLE NCT02624869 · Atherosclerotic Cardiovascular Disease This was a single-arm, open-label study with no comparison group, and its primary endpoint only counted adverse events, so it makes no efficacy comparison. Most participants rolled over from the earlier randomized HAUSER-RCT trial, but 13 children with homozygous disease were enrolled directly. Registry: NCT02624869 | 3 | Number of Participants With Treatment-emergent Adverse Events (TEAEs) (From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.) 2021-06-01 | Number of Participants With Treatment-emergent Adverse Events (TEAEs) (From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.): HeFH (Placebo in Parent Study): Evolocumab 420 mg QM — Any treatment-emergent adverse event (TEAE): 36 Participants; TEAE ≥ Grade 2: 25 Participants; TEAE ≥ Grade 3: 4 Participants; TEAE ≥ Grade 4: 0 Participants; Serious adverse events: 2 Participants; TEAE leading to discontinuation of evolocumab: 0 Participants; Fatal adverse events: 0 Participants | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM — Any treatment-emergent adverse event (TEAE): 69 Participants; TEAE ≥ Grade 2: 56 Participants; TEAE ≥ Grade 3: 2 Participants; TEAE ≥ Grade 4: 1 Participants; Serious adverse events: 2 Participants; TEAE leading to discontinuation of evolocumab: 0 Participants; Fatal adverse events: 0 Participants | HoFH: Evolocumab 420 mg QM — Any treatment-emergent adverse event (TEAE): 7 Participants; TEAE ≥ Grade 2: 5 Participants; TEAE ≥ Grade 3: 2 Participants; TEAE ≥ Grade 4: 0 Participants; Serious adverse events: 2 Participants; TEAE leading to discontinuation of evolocumab: 0 Participants; Fatal adverse events: 0 Participants | Weak signal | link ↗ |
VESALIUS-CV NCT03872401 · Atherosclerotic Cardiovascular Disease Registry: NCT03872401 | 3 | Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First (From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months); Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First (From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months) 2025-07-25 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (35)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (42)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (4)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (2)
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other PCSK9 drugs
Alirocumab, Inclisiran, Ebronucimab, Enlicitide, Laroprovstat and 13 more. Compare all 19 PCSK9 drugs
This mechanism is crowded: 19 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Evolocumab (Repatha): this drug | Approved | Monoclonal antibody | PCSK9 | Partial signal | NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877) | |
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | Weak signal | NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8) | |
| Bempedoic Acid (Nexletol) | Approved | Small molecule | ATP citrate lyase | Partial signal | NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446) NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421) | |
| Bempedoic Acid / Ezetimibe (Nexlizet) | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | Partial signal | NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49) | |
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | Partial signal | NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed | |
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 | |
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| Ezetimibe / Simvastatin (Vytorin) | Approved | Small molecule | HMG-CoA reductase / NPC1L1 | Reliable signal | NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81) NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons. | |
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | Reliable signal | NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090 | |
| Liraglutide (Victoza) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Ozempic) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9% | |
| Semaglutide (Rybelsus) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | Reliable signal | NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 | |
| Ticagrelor (Brilinta) | Approved | Small molecule | P2Y12 receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Tirzepatide (Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| AG2304 | Phase 3 | Small molecule | HMG-CoA reductase / NPC1L1 | Partial signal | No reviewed efficacy summary in this indication | |
| Alprostadil | Phase 3 | Small molecule | Prostaglandin E1 receptor | not yet graded | NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending | |
| Amlodipine / Valsartan / Atorvastatin (CJ-30061) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | Partial signal | No reviewed efficacy summary in this indication | |
| Beperminogene Perplasmid (HGF Plasmid) (Collategene) | Phase 3 | Gene therapy / editing | HGF (hepatocyte growth factor), Hepatocyte growth factor (HGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Cilostazol / Rosuvastatin (UI022 / UI023) | Phase 3 | Small molecule | PDE3 (phosphodiesterase 3) and HMG-CoA reductase | Reliable signal | NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior. | |
| Dalcetrapib | Phase 3 | Small molecule | CETP | Partial signal | NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01) | |
| Dapagliflozin (Farxiga / Forxiga) | Phase 3 | Small molecule | SGLT2 | not yet graded | No reviewed efficacy summary in this indication | |
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| Ebronucimab | Phase 3 | Monoclonal antibody | PCSK9 | Partial signal | NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). | |
| Enlicitide (Lipfendra) | Phase 3 | Peptide | PCSK9 | Reliable signal | NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6) | |
| Ezetimibe (Zetia) | Phase 3 | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | Reliable signal | NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001) NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01 | |
| Fimasartan / Atorvastatin / Ezetimibe (BR1017) | Phase 3 | Small molecule | AT1 receptor; NPC1L1; HMG-CoA reductase | Partial signal | NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025). | |
| Hyzetimibe | Phase 3 | Small molecule | NPC1L1 | Partial signal | NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001 NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。 | |
| Inclisiran (Leqvio) | Phase 3 | RNA / oligonucleotide | PCSK9 | Partial signal | NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) | |
| Laroprovstat | Phase 3 | Small molecule | PCSK9 | Reliable signal | NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) | |
| Laroprovstat / Rosuvastatin | Phase 3 | Small molecule | PCSK9 (laroprovstat component) + HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Lepodisiran | Phase 3 | RNA / oligonucleotide | LPA gene / apolipoprotein(a) mRNA | Partial signal | NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo) | |
| Lerodalcibep (Lerochol) | Phase 3 | Protein / enzyme therapeutic | PCSK9 | Reliable signal | NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001) NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005) | |
| Maridebart Cafraglutide (MariTide) | Phase 3 | Peptide | GLP-1R agonist; GIPR antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Muvalaplin | Phase 3 | Small molecule | Apolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interaction | Partial signal | NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo) | |
| NL003 | Phase 3 | Gene therapy / editing | Hepatocyte growth factor (HGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Obicetrapib | Phase 3 | Small molecule | CETP | Partial signal | NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571) NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48) | |
| Obicetrapib / Ezetimibe (Evlarco) | Phase 3 | Small molecule | CETP, NPC1L1 | Partial signal | NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) | |
| Olpasiran | Phase 3 | RNA / oligonucleotide | LPA gene / apolipoprotein(a) mRNA | Partial signal | NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W) | |
| Ongericimab (Junshida) | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001) NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001). | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pelacarsen | Phase 3 | RNA / oligonucleotide | Apolipoprotein(a) mRNA | Partial signal | NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1) | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| PMR (cilostazol ER) | Phase 3 | Small molecule | Phosphodiesterase 3 (PDE3) | Weak signal | No reviewed efficacy summary in this indication | |
| Pravafenix | Phase 3 | Small molecule | HMG-CoA reductase / PPAR-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| QLC7401 | Phase 3 | RNA / oligonucleotide | PCSK9 | not yet graded | No reviewed efficacy summary in this indication | |
| Ranolazine | Phase 3 | Small molecule | Cardiac late sodium current (late INa, Nav1.5) | Partial signal | NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482) | |
| Recaticimab | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001 NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons. | |
| Retatrutide | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| SAL003 | Phase 3 | Monoclonal antibody | PCSK9 | Partial signal | No reviewed efficacy summary in this indication | |
| Sarpogrelate (Anplag) | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Sumecigrel | Phase 3 | Small molecule | P2Y12 platelet receptor | Partial signal | NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin. | |
| SYH2053 | Phase 3 | RNA / oligonucleotide | PCSK9 | Partial signal | No reviewed efficacy summary in this indication | |
| Tafolecimab (Sintbilo) | Phase 3 | Monoclonal antibody | PCSK9 | Reliable signal | NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001 NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001) | |
| Ziltivekimab | Phase 3 | Monoclonal antibody | Interleukin-6 | Partial signal | NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed | |
| Neovasculgen | Phase 2/3 | Gene therapy / editing | VEGF165 gene therapy (angiogenic plasmid) | Partial signal | NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group | |
| ABP-745 | Phase 2 | Small molecule | NLRP3 inflammasome | not yet graded | No reviewed efficacy summary in this indication | |
| ACP-01 | Phase 2 | Biologic (subtype unspecified) | Autologous angiogenic cell precursor (ACP) therapy | Partial signal | NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed | |
| APAC | Phase 2 | Peptide | Vascular injury site glycocalyx / coagulation cascade | not yet graded | No reviewed efficacy summary in this indication | |
| BW-20829 | Phase 2 | RNA / oligonucleotide | Lipoprotein(a) [Lp(a)] production pathway | not yet graded | No reviewed efficacy summary in this indication | |
| CNIC-Ferrer Polypill (Trinomia) | Phase 2 | Small molecule | Multi-mechanism secondary-prevention polypill | Partial signal | No reviewed efficacy summary in this indication | |
| DNV001 | Phase 2 | RNA / oligonucleotide | PCSK9 | not yet graded | No reviewed efficacy summary in this indication | |
| EDP167 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | Weak signal | No reviewed efficacy summary in this indication | |
| Etribnabdione | Phase 2 | — | CB2 receptor and PPARγ (dual agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-1301 | Phase 2 | Small molecule | PCSK9 | Weak signal | No reviewed efficacy summary in this indication | |
| HRS-5346 | Phase 2 | Small molecule | Lipoprotein(a) [Lp(a)] formation | Partial signal | No reviewed efficacy summary in this indication | |
| HRS-5632 | Phase 2 | Unknown/Undisclosed | Lipoprotein(a) | Weak signal | No reviewed efficacy summary in this indication | |
| Human Acellular Vessel (Humacyte) | Phase 2 | Tissue-engineered Vessel (bioengineered) | tissue-engineered acellular vascular graft | Weak signal | NCT01872208: Primary patency 58%, primary-assisted patency 58%, secondary patency 74% at 24 months (Kaplan-Meier estimate, n=20) | |
| Kylo-11 | Phase 2 | RNA / oligonucleotide | Lipoprotein(a) | not yet graded | No reviewed efficacy summary in this indication | |
| Orticumab | Phase 2 | Monoclonal antibody | Oxidized low-density lipoprotein (oxLDL) epitope | Partial signal | No reviewed efficacy summary in this indication | |
| SAL0137 | Phase 2 | Small molecule | Apolipoprotein(a) [apo(a)] / apo(a)-apoB100 interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Selnoflast | Phase 2 | Small molecule | NLRP3 inflammasome | not yet graded | No reviewed efficacy summary in this indication | |
| COR-1004 | Phase 1 | — | PCSK9 | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10510 | Phase 1 | Small molecule | PCSK9 | not yet graded | No reviewed efficacy summary in this indication | |
| RBD7022 | Phase 1 | RNA / oligonucleotide | PCSK9 | Weak signal | Featured results are safety only in this race | |
| RN0191 | Phase 1 | RNA / oligonucleotide | PCSK9 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD8233 | Discontinued | RNA / oligonucleotide | PCSK9 | Partial signal | Featured results are safety only in this race |
Large race: only the 79 furthest-along competitors are listed; 44 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
12 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Repatha (Evolocumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
November 2026 (1)
What to watch
December 2026 (1)
What to watch
2027 (3)
March 2027 (1)
What to watch
May 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (2)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent